Real‐world experience with brolucizumab in pro re nata regimen in patients with neovascular age‐related macular degeneration previously treated with ranibizumab and aflibercept and without control of subretinal fluid

Documenti analoghi

• Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration
  di: Imadeddin Abu Ishkheidem, et al.
  Pubblicazione: (2025)
• Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration
  di: Yousif Subhi, et al.
  Pubblicazione: (2024)
• Recurrence after treat‐and‐extend suspension in neovascular age‐related macular degeneration: A real‐world analysis by macular neovascularization subtype
  di: Geoffrey Zeender, et al.
  Pubblicazione: (2026)
• Retinal imaging biomarkers in assessing treatment response when switching from aflibercept to faricimab in resistant neovascular age‐related macular degeneration cases
  di: Stamatina Kabanarou, et al.
  Pubblicazione: (2025)
• Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
  di: Petri Purola, et al.
  Pubblicazione: (2026)